Volume 84, Issue 4, Pages (October 2013)

Slides:



Advertisements
Similar presentations
Volume 83, Issue 2, Pages (February 2013)
Advertisements

Volume 65, Issue 1, Pages (January 2004)
Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells  B. Zhang, G. Ramesh, C.C. Norbury, W.B. Reeves 
Volume 64, Issue 6, Pages (December 2003)
Volume 72, Issue 3, Pages (August 2007)
Volume 78, Issue 3, Pages (August 2010)
Volume 79, Issue 9, Pages (May 2011)
Volume 78, Issue 11, Pages (December 2010)
Volume 76, Issue 1, Pages (July 2009)
Volume 83, Issue 2, Pages (February 2013)
Volume 85, Issue 4, Pages (April 2014)
Volume 81, Issue 9, Pages (May 2012)
Volume 78, Issue 4, Pages (August 2010)
Volume 91, Issue 2, Pages (February 2017)
Volume 78, Issue 4, Pages (August 2010)
Volume 66, Issue 3, Pages (September 2004)
Volume 76, Issue 7, Pages (October 2009)
Li-Wen Lai, Kim-Chong Yong, Yeong-Hau H. Lien  Kidney International 
Volume 82, Issue 6, Pages (September 2012)
Volume 84, Issue 3, Pages (September 2013)
Y.-H.H. Lien, K.-C. Yong, C. Cho, S. Igarashi, L.-W. Lai 
Renal denervation prevents long-term sequelae of ischemic renal injury
David J. Nikolic-Paterson, Shuang Wang, Hui Yao Lan 
Volume 74, Issue 10, Pages (November 2008)
Volume 85, Issue 1, Pages (January 2014)
Volume 67, Issue 5, Pages (May 2005)
Volume 64, Issue 1, Pages (July 2003)
IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy  J.-A. Moon,
Volume 66, Issue 6, Pages (December 2004)
Volume 88, Issue 3, Pages (September 2015)
Volume 80, Issue 9, Pages (November 2011)
Volume 62, Issue 1, Pages (July 2002)
Volume 70, Issue 7, Pages (October 2006)
Volume 69, Issue 1, Pages (January 2006)
Volume 77, Issue 5, Pages (March 2010)
Heterozygous disruption of activin receptor–like kinase 1 is associated with increased renal fibrosis in a mouse model of obstructive nephropathy  José.
Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy  S.C.W. Tang, J.C.K.
Yang Wang, Yi Ping Wang, Yuet-Ching Tay, David C.H. Harris 
Volume 58, Issue 1, Pages (July 2000)
Volume 84, Issue 5, Pages (November 2013)
Gilbert R. Kinsey, Liping Huang, Amy L. Vergis, Li Li, Mark D. Okusa 
Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats  Gopala K. Rangan, Yiping Wang, Yuet-Ching Tay,
Volume 58, Issue 1, Pages (July 2000)
Volume 60, Issue 1, Pages (July 2001)
Volume 86, Issue 4, Pages (October 2014)
Role of CD8+ cells in the progression of murine adriamycin nephropathy
Volume 79, Issue 4, Pages (February 2011)
Volume 92, Issue 3, Pages (September 2017)
Volume 68, Issue 1, Pages (July 2005)
Volume 76, Issue 5, Pages (September 2009)
Genetic deficiency of adiponectin protects against acute kidney injury
Volume 85, Issue 4, Pages (April 2014)
The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H–deficient mice  Jessy J. Alexander, Lee Chaves, Anthony Chang,
An unusual cause of acute renal failure
Volume 67, Issue 2, Pages (February 2005)
C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis  Gopala K. Rangan, Jeffrey W. Pippin, William.
Volume 75, Issue 6, Pages (March 2009)
Volume 79, Issue 2, Pages (January 2011)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
M.-J. Wu, M.-C. Wen, Y.-T. Chiu, Y.-Y. Chiou, K.-H. Shu, M.-J. Tang 
LncRNA ZEB1-AS1 Was Suppressed by p53 for Renal Fibrosis in Diabetic Nephropathy  Juan Wang, Jian Pang, Huiling Li, Jie Long, Fang Fang, Junxiang Chen,
CD4+ T cells: a potential player in renal fibrosis
Volume 68, Issue 3, Pages (September 2005)
Volume 80, Issue 10, Pages (November 2011)
Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist  Scott E. Wenderfer, Stanislaw.
Volume 67, Issue 6, Pages (June 2005)
Volume 84, Issue 1, Pages (July 2013)
Volume 65, Issue 1, Pages (January 2004)
Volume 75, Issue 2, Pages (January 2009)
Volume 79, Issue 11, Pages (June 2011)
Presentation transcript:

Volume 84, Issue 4, Pages 745-755 (October 2013) Discrete functions of M2a and M2c macrophage subsets determine their relative efficacy in treating chronic kidney disease  Junyu Lu, Qi Cao, Dong Zheng, Yan Sun, Changqi Wang, Xiao Yu, Ya Wang, Vincent W.S. Lee, Guoping Zheng, Thian K. Tan, Xin Wang, Stephen I Alexander, David C.H. Harris, Yiping Wang  Kidney International  Volume 84, Issue 4, Pages 745-755 (October 2013) DOI: 10.1038/ki.2013.135 Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 1 Adoptive transfer of M2a and M2c macrophages protects renal functional and structural injury in adriamycin-induced nephropathy (AN) mice. M2c macrophages were more effective than M2a macrophages in reducing proteinuria, glomerular sclerosis, tubular atrophy, and interstitial expansion. (a) Representative periodic acid–Schiff (PAS) sections of renal cortices at day 28 (original magnification × 200). (b–d) Serum creatinine, creatinine clearance, and proteinuria were assessed in normal mice, AN mice, and AN mice treated with M0, M2a, or M2c macrophages at day 28. (e–g) Quantitative analysis of structural changes in kidney. The values are mean±s.e.m. of evaluations for each group (n=6 per group). *P<0.05, **P<0.01, and ***P<0.001 versus AN+M0, #P<0.05 versus AN+M2a. Kidney International 2013 84, 745-755DOI: (10.1038/ki.2013.135) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 2 Adoptive transfer of M2a and M2c macrophages reduced renal inflammation. The reduction of CD4+ cell infiltration was greater in adriamycin-induced nephropathy (AN) mice treated with M2c than M2a macrophages. (a) F4/80+, CD4+, and CD8+ T-cell staining in renal cortices at day 28 (original magnification in high power field (hpf) × 200). (b–d) Quantitative analysis of F4/80+ cells, CD4+, and CD8+ T cells in normal mice, AN mice, and AN mice treated with M0, M2a, or M2c macrophages at day 28. The values are mean±s.e.m. of evaluations from each group (n=6 per group). *P<0.05, **P<0.01, and ***P<0.001 versus AN+M0, #P<0.05 versus AN+M2a. Kidney International 2013 84, 745-755DOI: (10.1038/ki.2013.135) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 3 Adoptive transfer of M2a and M2c macrophages ameliorated renal fibrosis; the antifibrotic effect of M2c macrophages was significantly superior to that of M2a. (a) Collagen I, α-smooth muscle actin (α-SMA), and fibroblast-specific protein 1 (FSP-1) staining in renal cortices at day 28 (original magnification × 200). (b–d) Quantitative analysis of collagen I-, α-SMA-, and FSP-1-positive staining area in normal mice, adriamycin-induced nephropathy (AN) mice, and AN mice treated with M0, M2a, or M2c macrophages at day 28. The values are mean±s.e.m. of evaluations from each group (n=6 per group). **P<0.01 and ***P<0.001 versus AN+M0; #P<0.05 versus AN+M2a. Kidney International 2013 84, 745-755DOI: (10.1038/ki.2013.135) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 4 M2c significantly increased regulatory T cells in renal draining lymph nodes. (a) Adoptive transfer of M2c macrophages increased Foxp3+ cells in local draining lymph nodes (LNs) at day 28 (original magnification × 400). (b–d) Quantitative analysis of Foxp3+ cells staining in LN, spleen, and kidney was performed in normal mice, control adriamycin-induced nephropathy (AN) mice, and AN mice treated with M0, M2a, or M2c macrophages. The values are mean ±s.e.m. of evaluations from each group (n=6 per group). *P<0.05 versus AN+M0 and ##P<0.01 versus AN+M2a. hpf, high power field. Kidney International 2013 84, 745-755DOI: (10.1038/ki.2013.135) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 5 Depletion of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in the peripheral blood. (a) BALB/c mice were transfused with M2a or M2c at day 5, following injection with PC61 at days 8 to 13 after adriamycin (ADR) injection. The blood was collected at days 5 and 15 after PC61 administration. (b–d) The fluorescence-activated cell sorting (FACS) result shows that the percentage of Tregs remained relatively stable in normal mice and control adriamycin-induced nephropathy (AN) mice on days 5 and 15, and Tregs were undetectable in AN mice treated with PC61, AN mice treated with PC61 and M2a macrophages, or AN mice treated with PC61 and M2c macrophages. The values are mean±s.e.m. of evaluations from each group (n=6 per group). ***P<0.001 versus AN. Kidney International 2013 84, 745-755DOI: (10.1038/ki.2013.135) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 6 Depletion of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in renal draining lymph node (LN), spleen, and kidney. (a) Number of Foxp3+ cells in local renal draining LNs, spleen, and kidney at day 28 (original magnification × 400). (b–d) Quantitative analysis of Foxp3+ cells staining in LN, spleen, and kidney was performed in normal mice, control adriamycin-induced nephropathy (AN) mice, AN mice treated with PC61, AN mice treated with PC61 and M2a macrophages, or AN mice treated with PC61 and M2c macrophages. The values are mean±s.e.m. of evaluations from each group (n=6 per group). ***P<0.001 versus AN. Kidney International 2013 84, 745-755DOI: (10.1038/ki.2013.135) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 7 Adoptive transfer of M2a or M2c macrophages provided equal protective effects against renal functional and structural injury after depletion of regulatory T cells (Tregs). (a) Periodic acid–Schiff (PAS) sections of renal cortices at day 28 (original magnification × 200). (b–d) Serum creatinine, creatinine clearance, and proteinuria were assessed in normal mice, adriamycin-induced nephropathy (AN) mice, AN mice treated with PC61, AN mice treated with PC61 and M2a macrophages, or AN mice treated with PC61 and M2c macrophages at day 28. (e–g) Quantitative analysis of structural changes in kidney (PAS). The values are mean±s.e.m. of evaluations from each group (n=6 per group). *P<0.05 and **P<0.01 versus AN+PC61. Kidney International 2013 84, 745-755DOI: (10.1038/ki.2013.135) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 8 Adoptive transfer of M2a or M2c macrophages reduced renal inflammation after depletion of regulatory T cells (Tregs). (a) F4/80+, CD4+, and CD8+ cell staining in renal cortices at day 28 (original magnification × 200). (b–d) Quantitative analysis of F4/80+, CD4+, and CD8+ T cells in normal mice, adriamycin-induced nephropathy (AN) mice, AN mice treated with PC61, AN mice treated with PC61 and M2a macrophages, or AN mice treated with PC61 and M2c macrophages at day 28. The values are mean±s.e.m. of evaluations from each group (n=6 per group). *P<0.05 and **P<0.01 versus AN+PC61. hpf, high power field. Kidney International 2013 84, 745-755DOI: (10.1038/ki.2013.135) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 9 Adoptive transfer of M2a or M2c macrophages ameliorated renal fibrosis after depletion of regulatory T cells (Tregs). (a) Collagen I, α-smooth muscle actin (α-SMA), and fibroblast-specific protein 1 (FSP-1) staining in renal cortices at day 28 (original magnification × 200). (b–d) Quantitative analysis of collagen I-, α-SMA-, and FSP-1-positive staining area in normal mice, adriamycin-induced nephropathy (AN) mice, AN mice treated with PC61, AN mice treated with PC61 and M2a macrophages, or AN mice treated with PC61 and M2c macrophages at day 28. The values are mean±s.e.m. of evaluations from each group (n=6 per group). *P<0.05, **P<0.01, and ***P<0.001 versus AN+PC61. Kidney International 2013 84, 745-755DOI: (10.1038/ki.2013.135) Copyright © 2013 International Society of Nephrology Terms and Conditions